Home/ Stocks/ PCVX

Vaxcyte, Inc. Common Stock

PCVX XNAS

$58.07 -1.89 (-3.21%) ▼ 15-min delayed

Open

$59.91

High

$60.08

Low

$56.73

Volume

1.30M

Market Cap

$8.76B

About Vaxcyte, Inc. Common Stock

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 507 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-284,302,000	$-1.97
Q1 2026	$0	$-320,622,000	$-2.30
Q3 2025	$0	$-212,830,000	$-1.56
Q2 2025	$0	$-166,573,000	$-1.22

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for PCVX yet. Check out our latest market news or earnings calendar.

Get PCVX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Vaxcyte, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.